The abstract is read at the publisher; the summary is JClub's.
Baseline serum metabolite profiles in 41 newly diagnosed type 1 diabetes participants are linked to teplizumab response, with a random forest model reaching 0.881 AUC in test data.
- Why it matters: Identifying who benefits from teplizumab is needed because response varies, and baseline biomarkers could enable more personalized treatment decisions in early type 1 diabetes.
- What they did: Using semitargeted metabolomics (liquid chromatography–high-resolution tandem mass spectrometry) on baseline samples, the study found 15 metabolites differing between responders and nonresponders and trained a supervised random forest with 70:30 split, fivefold cross-validation, 1,000 bootstrap iterations, and 1,000 permutations.
- The result: Responders (defined by <45% decline in baseline C-peptide at 2 years) showed higher TCA cycle metabolites, amino acid derivatives, and microbial metabolites, while nonresponders had elevated glutamate and acylcarnitines, supporting predictive baseline signatures pending further validation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.